Scholarlink

Background <p>In 2025, the Commission on Cancer (CoC) issued a quality measure recommending omission of sentinel node biopsy (SNB) in women 70 and over with cT1N0, hormone receptor positive (HR+), HER2neu negative invasive breast cancer undergoing breast conserving surgery. We examined historical performance of this measure.</p> Methods <p>Trends in omission of SNB and estimated performance rates (EPR) by facility (the proportion of patients in whom SNB was omitted at a facility) were examined from 2012–2023. Multivariate analysis demonstrated facility factors most strongly associated with median compliance rate of 25%.</p> Results <p>A total of 185,859 patients from the National Cancer Data Base (NCDB) met the aforementioned inclusion criteria. From 2012–2023, SNB was omitted in 43,513 (23.4%) of eligible patients. SNB omission rates were 14% in 2012 versus 44% in 2023. An EPR of 30% was achieved by 655 (52.9%) CoC facilities, 40% by 516 (41.9%) facilities, 50% by 393 (31.7%) facilities, 60% by 278 (22.5%) facilities, 70% by 155 (12.5%) facilities, and 80% by only 85 (6.9%) facilities from 2021–2023. Facilities with &gt;&#xa0;50% private insurance (OR 1.7, 95% CI:1.23–2.34), academic/teaching designation (OR 2.12, 95% CI:1.36–3.3), high volume (&gt;&#xa0;250 annual cases) (OR 2.07, 95% CI:1.35–3.18) and in certain census areas of the country were significantly associated with higher likelihood of achieving 25% EPR, the median EPR amongst all site, on multivariate analysis (<i>p</i>&#xa0;&lt;&#xa0;0.05).</p> Conclusion <p>SNB was omitted on less than half of eligible HR+, HER2neu negative early-stage breast cancer patients over age 70 in 2023, indicating an opportunity for quality improvement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performance

  • 期刊论文

  • 发表日期：

    2026年2月21日

查看全文
  • Gabrielle N. Yee,
  • Shelley Hwang,
  • Lee G. Wilke,
  • Laura M. Freedman,
  • Anthony J. Froix,
  • Emily Ray,
  • Kristine Kuchta,
  • Laura Eldridge,
  • Katharine A. Yao

摘要

Background

In 2025, the Commission on Cancer (CoC) issued a quality measure recommending omission of sentinel node biopsy (SNB) in women 70 and over with cT1N0, hormone receptor positive (HR+), HER2neu negative invasive breast cancer undergoing breast conserving surgery. We examined historical performance of this measure.

Methods

Trends in omission of SNB and estimated performance rates (EPR) by facility (the proportion of patients in whom SNB was omitted at a facility) were examined from 2012–2023. Multivariate analysis demonstrated facility factors most strongly associated with median compliance rate of 25%.

Results

A total of 185,859 patients from the National Cancer Data Base (NCDB) met the aforementioned inclusion criteria. From 2012–2023, SNB was omitted in 43,513 (23.4%) of eligible patients. SNB omission rates were 14% in 2012 versus 44% in 2023. An EPR of 30% was achieved by 655 (52.9%) CoC facilities, 40% by 516 (41.9%) facilities, 50% by 393 (31.7%) facilities, 60% by 278 (22.5%) facilities, 70% by 155 (12.5%) facilities, and 80% by only 85 (6.9%) facilities from 2021–2023. Facilities with > 50% private insurance (OR 1.7, 95% CI:1.23–2.34), academic/teaching designation (OR 2.12, 95% CI:1.36–3.3), high volume (> 250 annual cases) (OR 2.07, 95% CI:1.35–3.18) and in certain census areas of the country were significantly associated with higher likelihood of achieving 25% EPR, the median EPR amongst all site, on multivariate analysis (p < 0.05).

Conclusion

SNB was omitted on less than half of eligible HR+, HER2neu negative early-stage breast cancer patients over age 70 in 2023, indicating an opportunity for quality improvement.